Answers are grounded in this paper and cite their sources.
In vitro and in vivo research reveals that dopamine carbon dots lower inflammatory cytokines in periodontitis, suggesting a new immunomodulatory approach.
Periodontitis is a chronic inflammatory oral disease characterized by dysregulated host immune responses. Modulating the immune microenvironment has emerged as a promising therapeutic strategy to address the limitations of conventional treatments. To explore this approach, we developed uniformly sized dopamine-derived carbon dots (DACDs) with smooth surfaces via hydrothermal synthesis using dopamine as the precursor. The synthesized DACDs exhibited favorable biosafety and considerable photothermal conversion capability. In vitro experiments employing quantitative real-time PCR (qRT-PCR), Western blotting, and immunofluorescence staining demonstrated that DACDs synergized with mild photothermal therapy (MPTT) to significantly downregulate pro-inflammatory cytokine expression in RAW264.7 cells. In vivo studies further confirmed that the combined application of DACDs and MPTT markedly reduced periodontal inflammation and attenuated alveolar bone resorption, as evidenced by Micro-CT analysis and histological staining. Collectively, DACDs mitigate bone destruction by suppressing inflammatory cascades, establishing a novel and effective immunomodulatory strategy for the management of periodontitis.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: